[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Biobeats99 Avatar @Biobeats99 Luca Research Investment Club

Biotech companies are sharing updates on their research and development progress at various conferences, including ESMO. Several firms, such as Cantor Fitzgerald, Jefferies, and Bank of America, are providing analysis and insights on the biotech sector. Key areas of focus include advancements in cancer treatment, gene therapy, and rare diseases.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXXX% stocks XXXXX% cryptocurrencies XX% countries XXXX% social networks XXXX% technology brands XXXX% automotive brands XXXX%

Social topic influence $bmrn #7, $ntla #9, $alny #13, $crsp #15, $beam #23, $rxrx #13, $arwr #26, $ions #6, $edit 15.38%, $kymr #32

Top assets mentioned BioMarin Pharmaceutical, Inc. (BMRN) Intellia Therapeutics, Inc (NTLA) Alnylam Pharmaceuticals, Inc. (ALNY) CRISPR Therapeutics AG (CRSP) BEAM (BEAM) Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Arrowhead Research Corporation (ARWR) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Kymera Therapeutics, Inc. Common Stock (KYMR) Sarepta Therapeutics, Inc. (SRPT) Vertex Protocol (VRTX) Nuvalent, Inc. Class A Common Stock (NUVL) Dyne Therapeutics, Inc. Common Stock (DYN) Bluefin (BLUE) Praxis Precision Medicines, Inc. Common Stock (PRAX) Axsome Therapeutics, Inc (AXSM) uniQure N.V. (QURE) Goldman Sachs (GS) CG Oncology, Inc. Common stock (CGON) Amgen, Inc. (AMGN) Denali Therapeutics Inc. Common Stock (DNLI) Revolution Medicines, Inc. Common Stock (RVMD) Cogent Biosciences, Inc. Common Stock (COGT) Biogen Inc (BIIB) Immunogen Inc (IMGN) Adverum Biotechnologies, Inc. Common Stock (ADVM) IDEAYA Biosciences, Inc. Common Stock (IDYA) Merus N.V. Common Shares (MRUS) Crinetics Pharmaceuticals, Inc. (CRNX) Disc Medicine, Inc. Common Stock (IRON) Supernus Pharmaceuticals, Inc. (SUPN) Sage Therapeutics, Inc (SAGE) SuperRare (RARE) Acadia Pharmaceuticals Inc. (ACAD) Neurocrine Biosciences, Inc. (NBIX) Taraxa (TARA) Insmed, Inc. (INSM) Bristol-Myers Squibb Co (BMY) AbbVie Inc (ABBV) Johnson & Johnson (JNJ) Eli Lilly and Company (LLY) Dawn Protocol (DAWN) Viking Therapeutics, Inc (VKTX) Arcutis Biotherapeutics, Inc. Common Stock (ARQT) One Cash (ONC) Incyte Corporation (INCY) Summit Therapeutics Inc. Common Stock (SMMT) Coursera, Inc. (COUR) Stride, Inc. (LRN) Strategic Education, Inc. Common Stock (STRA) Grand Canyon Education, Inc (LOPE) BRIGHT HORIZONS FAMILY SOLUTIONS INC. (BFAM)

Top Social Posts

Top posts by engagements in the last XX hours

"U.S. Small & Mid Cap Biotechnology: Key Takeaways from KOL Call on Heme Malignancies: Read-through for Nurix (NRIX) BeOne (ONC) and Incyte (INCY) Full report in Telegram (in bio)👆 $NRIX $ONC $INCY $BMRN $SRPT $ARWR $ALNY $IONS $BLUE $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE"
X Link 2025-10-17T05:24Z XXX followers, XXX engagements

"TD Cowen QUICK TAKE - SMMT - Mgmt Dinner Highlights: One Step Closer To Transforming NSCLC & Onc At-Large Full report in Telegram (in bio)👆 $SMMT $AKESO $LEGN $AMGN $BMRN $SRPT $IONS $ALNY $ARWR $BLUE $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE $ABEO $PGEN $DNLI $FATE $SGMO"
X Link 2025-10-20T15:54Z XXX followers, XXX engagements

"JP Morgan China Healthcare: Key takeaways from 11th batch of national centralized drug procurement Full report in bio $ZLAB $IMAB $AKESO $EGRNF $HLVX $ALNY $ARWR $IONS $BLUE $BMRN $SRPT $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE $PGEN $DNLI $FATE $ADVM $VERV $PRAX $GLPG"
X Link 2025-10-29T11:20Z XXX followers, XXX engagements

"Goldman Sachs Henlius Biotech Next-gen IO-ADC to lead pipeline globalization; initiate at Buy Full report in bio $2696.HK $ZLAB $IMAB $AKESO $EGRNF $HLVX $ARWR $ALNY $IONS $BLUE $BMRN $SRPT $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE $PGEN $DNLI"
X Link 2025-11-03T22:50Z XXX followers, XXX engagements

"Goldman Sachs Phoenix Education Partners (PXED): Leading Online University with Focus on Student Outcomes and Sustainable Growth; Initiate at Neutral Full report in bio $PXED $CHGG $COUR $LRN $STRA $LOPE $APEI $PRDO $BFAM $TWOU $PSO $RELX $UDMY $DUOL $BIDU $META $GOOGL"
X Link 2025-11-03T22:55Z XXX followers, XXX engagements

"JP Morgan Webinar on X Dec - US Pharma & Biotech Outlook: Global Potential of China Innovative Drugs Full video in bio $ZLAB $IMAB $AKESO $EGRNF $HLVX $ARWR $ALNY $IONS $BLUE $BMRN $SRPT $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE $PGEN $DNLI $FATE $ADVM $VERV $PRAX $GLPG"
X Link 2025-11-12T08:50Z XXX followers, XXX engagements

"Jefferies Deep Dive ALX Oncology (ALXO BUY): Focused High-Value Pipeline on Biomarker IO and ADC - Initiate at BUY PT $X Full report in bio $ALXO $IMCR $LEGN $KURA $IDYA $RVMD $TNGX $ZYME $MRUS $IMNM $NUVL $RPTX $PYXS $COGT $CRNX $SNDX $IRON $NRIX $REPL $ANAB $VTYX $INSM"
X Link 2025-11-14T23:11Z XXX followers, XXX engagements

"Goldman Sachs SSE LN: SSE Deep dive: to raise or not to raise BUY United Kingdom Full report in bio $SSE $NGG $CNA $DAX $ENEL $IBE $ORSTED $RWE $VOD $BTI $BP $SHEL $TTE $EQNR $NEE $DUK $D $AEP $SO $XEL $EXC $ED $PCG $PEG $PPL $EIX $AWK $WEC $CMS $NRG"
X Link 2025-11-14T23:24Z XXX followers, XXX engagements

"RBC SUPN US: Supernus Pharmaceuticals Initial Opinion Firing on all cylinders with trifecta of branded CNS launches: Initiate Buy $XX PO Full report in bio $SUPN $AXSM $RLMD $SAGE $CYT $LLY $BMY $BIIB $ABBV $JNJ $PFE $AMGN $VRTX $BMRN $SRPT $IONS $ALNY $ARWR $BLUE"
X Link 2025-11-14T23:42Z XXX followers, XXX engagements

"Goldman Sachs ALH US: Alliance Laundry Initial Opinion The (Speed) Queen of Laundry: initiate at Buy BUY Full report in bio $ALH $WHR $IR $LII $TT $CARR $AAON $LEG $MHK $MAS $FBIN $AWI $JCI $GNRC $SWK $HD $LOW $TSLA $GE $HON $EMR $ITW $DHR $MMM $ETN $ROK $CAT $DE $PH"
X Link 2025-11-14T23:42Z XXX followers, XXX engagements

"Cantor Fitzgerald CytomX Therapeutics is transforming from an underdog to a serious contender with growing confidence in the potential of its CX-2051 program. Full report in Bio $CTMX $RXRX $IMGN $ADAG $ABUS $BCAB $DAWN $KURA $NTLA $PRQR"
X Link 2025-11-20T17:18Z XXX followers, XXX engagements

"Cantor Fitzgerald Key highlights from the initiation webinar on DiaMedica Therapeutics showcase the company's promising pipeline and growth strategy. Full report in Bio $DMAC $RXRX $IMGN $ADAG $ABUS $BCAB $DAWN $KURA $NTLA $PRQR"
X Link 2025-11-20T17:29Z XXX followers, XXX engagements

"Barclays GE Healthcare acquires Intelerad for $XXX billion significantly expanding its cloud-based SaaS portfolio across multiple care settings; Equal Weight rating reiterated. Full report in Bio $GEHC $SIEM $PHG $BAX $MDT $BSX $RMD $EW $ABT $JNJ $DXCM $ISRG $ZBH $STE $TFX"
X Link 2025-11-21T16:02Z XXX followers, XXX engagements

"Piper Sandler Fourth quarter 2025 remains catalyst-rich with multiple key events expected through year-end for ACRV CAPR CRSP DYN FULC GLUE INO KYMR and MIST. Full report in Bio $ACRV $CAPR $CRSP $DYN $FULC $GLUE $INO $KYMR $MIST $BEAM $NTLA $EDIT $RXRX $IMGN $BCAX"
X Link 2025-11-24T05:26Z XXX followers, XXX engagements

"Mizuho Key opinion leaders express cautious optimism for Tinlarebant ahead of this week's Phase X data readout in Stargardt disease. Full report in Bio $BLTE $RETA $EYEN $OCUL $ADVM $RGNX $BEAM $NTLA $EDIT $CRSP $FDMT $RXRX $KYMR $IMGN $AGIO"
X Link 2025-11-24T16:09Z XXX followers, XXX engagements

"Jefferies BioMarin Pharmaceutical: The PDUFA delay for ASND is viewed as a procedural rather than clinical issue with limited fundamental impact. BUY rating maintained with confidence in the program's approval prospects in 1H26. Full report in Bio $BMRN $RARE $BGNE $UTHR"
X Link 2025-11-27T18:35Z XXX followers, XXX engagements

"Piper Sandler BioInsights report highlights the ongoing revolution in RNA medicines showcasing technological advancements and therapeutic potential across key developers in the sector. Full report in Bio $ABBV $ALNY $AMGN $ARCT $ARWR $BIIB $BMRN $BMY $CAMP $CAPR $CRSP $DYN"
X Link 2025-12-01T16:14Z XXX followers, XXX engagements

"Jefferies Minerva receives FDA alignment on the design of a new pivotal Phase X trial for its therapy in negative symptoms of schizophrenia a positive regulatory step. Full report in Bio $NERV $SAGE $ALKS $ACAD $NBIX $SUPN $AXSM $SEEL $BCLI $MNKD $ATXI $JNJ $ABBV $BIIB"
X Link 2025-12-01T19:14Z XXX followers, XXX engagements

"TD Cowen RVMD named a top pick for 2026 highlighted for its revolutionary approach to treating RAS-positive solid tumors representing a significant market opportunity. Full report in Bio $RVMD $KYMR $RXRX $DYN $CGON $NUVL $TARA $ACRV $SVRA $PRAX $AXSM $BEAM"
X Link 2025-12-03T19:22Z XXX followers, XXX engagements

"Jefferies Praxis Precision Medicines reports two positive clinical developments: one in Essential Tremor and another in a rare form of epilepsy reinforcing its pipeline's potential. BUY rating maintained. Full report in Bio $PRAX $AXSM $SAGE $SEEL $BIIB $NBIX $ACAD $SUPN"
X Link 2025-12-05T05:32Z XXX followers, XXX engagements

"Finger On The Pulse Full report in Telegram(in title)👆 $SMID $MBRX $OGEN $BCDA $TFFP $GTBP $LIXT $CBI $AZTR $VAXX $RAIN $AIMD $HEPA $TRVN $RVV $SNGX $DCL $FNCH $SONN $XCUR $APLIF $ADIL $ALLR $PNT $PRTG $GNPX $PHIL $PALI $ONCO $ENSC $APVO $TRA $CING $INFI $DMTK $BIOS $NEXI"
X Link 2025-03-24T14:13Z XXX followers, 2692 engagements

"Needham HRMY reports positive results for Pitolisant GR supporting a planned NDA submission in early 2026. BUY rating maintained with $XX price target. Full report in Bio $HRMY $AXSM $JAZZ $AVDL $SUPN $SAGE $SEEL $BCLI $MNKD $PRTA"
X Link 2025-11-24T16:19Z XXX followers, XXX engagements

"Jefferies Structure Therapeutics' robust Phase X data for its oral GLP-1 receptor agonist solidifies its profile as a Phase 3-ready asset in the competitive obesity market. Full report in Bio $GPCR $LLY $NVO $AMGN $ALT $VKTX $CORT $BIIB $MNKD $KYMR $RXRX $CGON $DYN $AXSM"
X Link 2025-12-08T17:38Z XXX followers, XXX engagements

"Jefferies Most Read Reports and Top Questions from the Buyside Oct 2025 Edition Full report in bio $KURA $IDYA $LEGN $IMCR $TNGX $RVMD $ZYME $MRUS $IMNM $NUVL $RPTX $ALXO $PYXS $COGT $CRNX $SNDX $IRON $NRIX $REPL $ANAB $VTYX $INSM $ARQT $PRAX $RARE $FGEN $GLPG $NBIX $ACAD"
X Link 2025-11-02T16:01Z XXX followers, XXX engagements

"Goldman Sachs KeyMed A key player in China's booming immunology; Initiate at Buy XX pages Full report in bio $ZLAB $IMAB $AKESO $EGRNF $HLVX $ARWR $ALNY $IONS $BLUE $BMRN $SRPT $VRTX $EDIT $CRSP $NTLA $BEAM $RGNX $QURE $PGEN $DNLI $FATE $ADVM"
X Link 2025-11-03T22:48Z XXX followers, XXX engagements

"Goldman Sachs China Healthcare: Biotechnology: From Survive to Thrive - Deep-dive on China's small-cap biotech; initiate on Abbisko at Buy Full report in bio $2256.HK $ZLAB $IMAB $AKESO $EGRNF $HLVX $2162.HK $2696.HK $ARWR $ALNY $IONS $BLUE $BMRN $SRPT $VRTX $EDIT $CRSP"
X Link 2025-11-03T22:51Z XXX followers, XXX engagements

"Barclays CLLS - 3Q25 incremental; eyes on ASH updates Full report in bio $CLLS $LEGN $IMCR $KURA $IDYA $RVMD $TNGX $ZYME $MRUS $IMNM $NUVL $RPTX $ALXO $PYXS $COGT $CRNX $SNDX $IRON $NRIX $REPL $ANAB $VTYX $INSM $ARQT $PRAX $RARE $FGEN $GLPG $NBIX $ACAD $VKTX"
X Link 2025-11-09T20:49Z XXX followers, XXX engagements

"LifeSci Capital Deep Dive ADAG (OUTPERFORM $XXXX PT): Realizing the True Potential of CTLA-4; Initiating at OUTPERFORM and $X PT Full report in bio $ADAG $IMCR $LEGN $KURA $IDYA $RVMD $TNGX $ZYME $MRUS $IMNM $NUVL $RPTX $ALXO $PYXS $COGT $CRNX $SNDX $IRON $NRIX $REPL $ANAB"
X Link 2025-11-14T23:13Z XXX followers, XXX engagements

"Bank of America Janux Therapeutics' price objective has been adjusted. The report frames the near-term catalyst for JANX007 as a binary outcome posing the question of which type of news investors should prepare for first. Full report in Bio $JANX $KYMR $CGON $IMGN $RXRX $DYN"
X Link 2025-12-02T15:45Z XXX followers, XXX engagements

"Cantor Fitzgerald Analysis of Arrowhead's pooled baseline data from its Phase X SHTG trial indicates a well-characterized patient population reducing clinical risk ahead of topline results. Positive stock outlook maintained. Full report in Bio $ARWR $ALNY $IONS $VRTX $NUVL"
X Link 2025-12-05T05:34Z XXX followers, XXX engagements

"TD Cowen HALO named a top pick for 2026 with confidence centered on the strategic value and commercial potential of its ENHANZE drug delivery technology platform. Full report in Bio $HALO $RXRX $KYMR $CGON $DYN $TARA $ACRV $SVRA $PRAX $AXSM $NUVL $BEAM $ARWR $ALNY $BMRN"
X Link 2025-12-05T18:14Z XXX followers, XXX engagements

"TD Cowen ASH 2025 data and a clear 2026 catalyst path signal a major upcoming growth phase ("Boom") for next-generation IKZF1/3 degraders in multiple myeloma. Full report in Bio $CCCC $KYMR $RXRX $CGON $DYN $TARA $ACRV $SVRA $PRAX $AXSM $NUVL $BEAM $NTLA $CRSP $BMY $AMGN"
X Link 2025-12-05T18:16Z XXX followers, XXX engagements

"Wolfe Research Summary ahead of a key binary event for Kymab (KYMR) this Monday December 8th. The event likely a major clinical data readout or regulatory decision is expected to cause significant stock volatility. Full report in Bio $KYMR $RXRX $DYN $CGON $NUVL $TARA"
X Link 2025-12-06T15:09Z XXX followers, XXX engagements

"Wedbush Initial clinical data for WVE-007 demonstrates a transformative therapeutic profile potentially opening a significant new market in neuromuscular and neurological disorders. Full report in Bio $WVE $IONS $ALNY $BMRN $RARE $NTLA $CRSP $BEAM $EDIT $SRPT $KYMR $RXRX"
X Link 2025-12-08T15:46Z XXX followers, XXX engagements

"Piper Sandler Cogent Biosciences reports a 'hat trick' of positive updates for bezuclastinib: positive data in Advanced Systemic Mastocytosis (AdvSM) and deepening responses in Non-Advanced SM reinforcing its best-in-class potential. Full report in Bio $COGT $KYMR $RXRX $DYN"
X Link 2025-12-08T19:35Z XXX followers, XXX engagements